A proposal for funding for the 7th International Symposium on von Hippel Lindau D

描述（由申请人提供）：VHL是一种遗传性疾病，在世界上每32，000人中就有1人患病，并导致体内多个器官发生肿瘤。 肾癌是该疾病最具破坏性的表现之一，并继续导致VHL患者的显著发病率。 VHL家庭联盟（VHL）的使命支持国家癌症研究所的使命：减轻癌症患者的痛苦。 VHL通过改善诊断，治疗和生活质量来支持受疾病影响的个人和家庭。 VHL通过与医疗保健专业人员和研究人员合作，了解VHL和其他罕见遗传癌症疾病的功能，以找到管理它们的方法来实现这一目标。 第七届国际VHL研讨会将通过以下方式实现这些目标： 促进已建立的研究人员和临床医生与受疾病影响的个人之间的合作。 向与会者提供最先进的管理信息，以便及早识别疾病的表现。 将形成对VHL和其他类似于VHL表现的散发性疾病的研究之间的联盟。 在专题讨论会上，国家和国际专家将提供教学讲座和提问时间，讨论该疾病涉及多器官的问题。 第一天将涵盖VHL疾病的基础科学方面，重点是最近对VHL蛋白质的各种生化功能的分子理解。 第二天将分为两个一般部分，其中第一部分将集中在VHL疾病的遗传基础上，重点是VHL疾病中新兴的基因型表型相关性。 第二次会议将涵盖最近的治疗方案更新和VHL疾病的诊断和预后指标。 第三天将包括三个会议：基因检测，心理方面，以及小组和开放论坛，讨论围绕VHL疾病的健康和研究问题。

DESCRIPTION (provided by applicant): VHL is a genetic disorder that affects 1 person in 32,000 in the world and results in the development of tumors in multiple organs in the body. Kidney cancer is one of the most devastating manifestations of the disease and continues to lead to significant morbidity in patients with VHL. The mission of VHL Family Alliance (VHL) supports that of the National Cancer Institute: to reduce pain and suffering of those with cancer. VHL supports individuals and families affected by the disease through improving diagnosis, treatment and quality of life. VHL achieves this through working in partnership with health care professionals and researchers to understand how VHL and other rare genetic cancer disorders function in order to find methods to manage them. The 7th International VHL symposium will reach these objectives by: Fostering collaboration between established researchers and clinicians together with individuals affected by the disease. Providing state-of-the-art management information to attendees to enable earlier identification of manifestations of the disease. Alliances between research into VHL and other sporadic disease analogous to the manifestations of VHL will be formed. At the symposium national and international experts will provide didactic lectures and question-periods addressing the multi-organ involvement of the disease. The first day will cover the basic science aspect of VHL disease with emphasis on the recent molecular understanding of the various biochemical functions scribed to the VHL protein. The second day will be divided into two general sections, where the first section will focus on the genetic basis of VHL disease with emphasis on the emerging genotype pheno-type correlation in VHL disease. The second session will cover the recent treatment protocol updates and diagnostic and prognostic indicators of VHL disease. The third day will cover three sessions: Genetic testing, psychological aspects, and small group and open forums to discuss health and research issues surrounding VHL disease.